# Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B

> **NCT02862106** · PHASE2 · COMPLETED · sponsor: **Chongqing Jiachen Biotechnology Ltd.** · enrollment: 209 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** εPA-44

## Key facts

- **NCT ID:** NCT02862106
- **Lead sponsor:** Chongqing Jiachen Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862106, "Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT02862106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*